Research
Energy balance
Cagrilintide-semaglutide resulted in a mean percent change in body weight of -20.4% from baseline to week 68 compared to -3.0% with placebo.
Cagrilintide-semaglutide may be an effective treatment option for significant weight loss in adults with overweight or obesity.
StrongSupportsmedium confidence
The estimated mean percent change in body weight from baseline to week 68 was -20.4% with cagrilintide-semaglutide as compared with -3.0% with placebo.
Why this rating
Based on a phase 3a, multicenter, double-blind, placebo-controlled trial.
Source
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
W. Timothy Garvey et al. · New England Journal of Medicine · 2025
DOI 10.1056/nejmoa2502081
rct · n=3417Cited 138×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →